the performance and the financial status for the year 2019 ended December 31, 2019 of the Company and its subsidiaries, as shown below: (Unit : Thousand Baht) 2019 2018 Change %Change Revenue 910,707
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
consumption and investment. The slower growth is expected to continue in 3Q19 since the external factors remain unsolved. Although private consumption was supported by sales promotion and government measures
equity, so the marketing activities has been arranged with sales plan improvement and promotion efficiency spending. 95.07% 95.71% 95.53% 4.93% 4.29% 4.47% 3Q18 2Q19 3Q19 Sales Other Income 63.04% 64.71
observed a growth in subsidiary business especially in distress debt management and mobile phone distributor. The details of the Company’s performance are explained as follows: 2016 2017 Change MB % MB % MB
except facial cleansers and gift sets which managed to grow significantly at a rate of 8 9 .4 7 % and 36 .25% respectively thanks to sales promotion campaigns that attracted customers and popularity of
expect the improvement after the pandemic of COVID-19 ends. Table 1 : Sales Revenue by Product Line for the Three Months ended 31 March (3M YoY) Sales by geography Consolidated financial statements Change
on investment property. Thus, the details of the Company’s performance are explained as follows: 2016 2017 Change MB % MB % MB % Rental and Service Income 545.2 97.1% 708.0 94.9% 162.8 29.9% Food and
Company’s performance are explained as follows: 2016 2017 Change MB % MB % MB % Rental and Service Income 545.2 97.1% 708.0 94.9% 162.8 29.9% Food and Beverage Income 0.0 0.0% 18.4 2.5% 18.4 n.a. Other Income
Unit : Million Baht For the 3 months Change between QoQ Change between YoY For the 6 months Change between YoY Q2/18 Q1/18 Q2/17 Amount % Amount % Jun. 18 Jun 17 Amount % Revenues from medical services